How accurate is an initial, negative prostate biopsy at predicting risk for prostate cancer-specific mortality?

A new paper in this week’s issue of Lancet Oncology comes from analysis of data on the outcomes of > 60,000 men given a prostate biopsy for risk of prostate cancer in Denmark between 1995 and 2011 and followed for up to 20 years thereafter. … READ MORE ..

Nadir PSA predicts survival after radiation and androgen deprivation for unfavorable risk patients

The following commentary addresses the article on risk for recurrent prostate cancer that we had mentioned briefly yesterday.

If a treatment isn’t working, we want to know as quickly as possible so we can try a salvage therapy while it can still make a difference. … READ MORE …

Population-based rates of treatment for prostate cancer: 2007-2012

The population-based rate of Medicare patients getting treatment for prostate cancer dropped by 42 percent from 2007 to 2012 … but this drop did not occur in patients who had a high risk of dying from a cause other than prostate cancer within 10 years, who are arguably among those who least need immediate treatment for prostate cancer (and especially for low-risk forms of prostate cancer). … READ MORE …

Prostate cancer in men with advanced bladder cancer

A new article in the journal Urologic Oncology has highlighted an association between the occurrence of advanced bladder cancer and the related finding of prostate cancer among such patients who have their prostate removed along with their bladder at the time of initial surgery  for the bladder cancer (i.e., a radical cystoprostatectomy). … READ MORE …

Prostate cancer statistics in America, 2017

As it does every year, the American Cancer Society (ACS) has just published it’s annual update cancer statistics update: Cancer Facts & Figures 2017. Those who are interested are of course welcome to peruse this detailed document for themselves. What follows is a quick summary of the prostate cancer-related data in the ACS update. … READ MORE …

New grade group system predicts risk for prostate cancer-specific mortality

According to a report on the Renal & Urology News web site this morning, a new paper about to be published on line in European Urology (by He et al.) has shown that the new ISUP staging system can be used to project risk for prostate cancer-specific mortality, “regardless of treatment received or clinical stage at diagnosis”. … READ MORE …

Starting the new year with two of the usual controversies

Strictly speaking, JAMA Oncology actually ended the old year (in its issue on December 29, 2016), rather than beginning the new one, with two articles, a letter to the editor, and an editorial that deal with two of the more controversial issues that affect the way we think about the management of prostate cancer. … READ MORE …